HighTower Advisors
ONCT

HighTower Advisors’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

HighTower Advisors’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-500
Closed -$9K – 3567
2022
Q3 		$9K Buy
+500
New +$10.7K ﹤0.01% 3031

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $324M AUM 37.9% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HighTower Advisors's ONCT Position: Q4 2022 in Review

HighTower Advisors sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2022, closing a stake of 500 shares — an estimated $9K sold.

HighTower Advisors first reported a position in ONCT in Q3 2022 and held it in 1 quarter. The position peaked at $9K in Q3 2022. 58 funds tracked by Wall St. Rank hold ONCT as of Q4 2022.

  • HighTower Advisors reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • HighTower Advisors sold 500 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $9K.
  • HighTower Advisors first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • HighTower Advisors's Oncternal Therapeutics, Inc. Common Stock position peaked at $9K in Q3 2022.
  • 58 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2022.

Based on HighTower Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.